Anita C Thomas

List of Publications by Year
in descending order

69 papers	2,369 citations	201674 27 h-index	206112 48 g-index
75 all docs	75 docs citations	75 times ranked	3763 citing authors

#	Article	IF	Citations
1	<i>In Vitro</i> Sustained Release of LMWH from MgAl-layered Double Hydroxide Nanohybrids. Chemistry of Materials, 2008, 20, 3715-3722.	6.7	247
2	Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thrombosis and Haemostasis, 2009, 101, 1006-1011.	3.4	143
3	Ã¢â,¬Å“Of Mice and MenÃ¢â,¬Â Arginine Metabolism in Macrophages. Frontiers in Immunology, 2014, 5, 479.	4.8	141
4	Advances in vascular tissue engineering. Cardiovascular Pathology, 2003, 12, 271-276.	1.6	123
5	Dog peritoneal and pleural cavities as bioreactors to grow autologous vascular grafts. Journal of Vascular Surgery, 2004, 39, 859-867.	1.1	117
6	Nitric Oxide Synthase: Non-Canonical Expression Patterns. Frontiers in Immunology, 2014, 5, 478.	4.8	106
7	A casein variant in cow's milk is atherogenic. Atherosclerosis, 2003, 170, 13-19.	0.8	98
8	Complement C5a inhibition reduces atherosclerosis in ApoE ^{â€“/â€“} mice. FASEB Journal, 2011, 25, 2447-2455.	0.5	76
9	Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells. Biomaterials, 2010, 31, 5455-5462.	11.4	69
10	Foam Cell Formation In Vivo Converts Macrophages to a Pro-Fibrotic Phenotype. PLoS ONE, 2015, 10, e0128163.	2.5	65
11	S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis, 2005, 183, 65-73.	0.8	63
12	Genomics of Foam Cells and Nonfoamy Macrophages From Rabbits Identifies Arginase-I as a Differential Regulator of Nitric Oxide Production. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 571-577.	2.4	62
13	Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells. Biomaterials, 2011, 32, 7234-7240.	11.4	62
14	Macrophage: SHIP of Immunity. Frontiers in Immunology, 2014, 5, 620.	4.8	54
15	Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thrombosis and Haemostasis, 2009, 101, 1006-11.	3.4	53
16	LIVER PRESERVATION WITH UW SOLUTION. Transplantation, 1990, 49, 869-871.	1.0	51
17	Galectin-3 Identifies a Subset of Macrophages With a Potential Beneficial Role in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1491-1509.	2.4	49
18	Expression of growth factor receptors on arterial smooth muscle cells. Dependency on cell phenotype and serum factors. Atherosclerosis, 1995, 118, 77-87.	0.8	45

#	Article	IF	Citations
19	Neointima Formed by Arterial Smooth Muscle Cells Expressing Versican Variant V3 Is Resistant to Lipid and Macrophage Accumulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1309-1316.	2.4	43
20	Antibodyâ€Targeted Drug Delivery to Injured Arteries Using Layered Double Hydroxide Nanoparticles. Advanced Healthcare Materials, 2012, 1, 669-673.	7.6	43
21	Matrix metalloproteinases can facilitate the heparanase-induced promotion of phenotypic change in vascular smooth muscle cells. Atherosclerosis, 1999, 145, 97-106.	0.8	41
22	Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques. Basic Research in Cardiology, 2013, 108, 319.	5.9	41
23	Layered double hydroxide nanoparticles: Impact on vascular cells, blood cells and the complement system. Journal of Colloid and Interface Science, 2018, 512, 404-410.	9.4	39
24	EVALUATION OF UW SOLUTION IN RAT KIDNEY PRESERVATION. Transplantation, 1990, 49, 1051-1054.	1.0	35
25	EVALUATION OF UW SOLUTION IN A RAT KIDNEY PRESERVATION MODEL. Transplantation, 1990, 49, 872-875.	1.0	35
26	Classical and Alternative Activation and Metalloproteinase Expression Occurs in Foam Cell Macrophages in Male and Female ApoE Null Mice in the Absence of T and B Lymphocytes. Frontiers in Immunology, 2014, 5, 537.	4.8	35
27	miR-15a/-16 Inhibit Angiogenesis by Targeting the Tie2 Coding Sequence: Therapeutic Potential of a miR-15a/16 Decoy System in Limb Ischemia. Molecular Therapy - Nucleic Acids, 2019, 17, 49-62.	5.1	34
28	Effect of Matrix Metalloproteinase-9 Knockout on Vein Graft Remodelling in Mice. Journal of Vascular Research, 2010, 47, 299-308.	1.4	29
29	Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF â€1/ CXCR4 signalling pathway. European Journal of Heart Failure, 2020, 22, 1568-1581.	7.1	25
30	Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems. Current Pharmaceutical Design, 2013, 19, 6330-6339.	1.9	25
31	Coronary artery mechanics induces human saphenous vein remodelling <i>via</i> recruitment of adventitial myofibroblast-like cells mediated by Thrombospondin-1. Theranostics, 2020, 10, 2597-2611.	10.0	23
32	Leukaemia inhibitory factor retards the progression of atherosclerosis. Cardiovascular Research, 2003, 58, 222-230.	3.8	22
33	Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. Atherosclerosis, 2004, 176, 73-81.	0.8	20
34	Animal Models for Studying Neointima Formation. Current Vascular Pharmacology, 2010, 8, 198-219.	1.7	19
35	Animal models for studying vein graft failure and therapeutic interventions. Current Opinion in Pharmacology, 2012, 12, 121-126.	3.5	19
36	Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. Journal of Clinical Investigation, 2022, 132, .	8.2	18

#	Article	IF	Citations
37	Resistance of ovine, caprine and bovine endothelial cells to Clostridium perfringens type D epsilon toxin in vitro. Veterinary Research Communications, 1999, 23, 275-284.	1.6	17
38	Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer. Thrombosis and Haemostasis, 2009, 102, 145-152.	3.4	17
39	Conjugation of an antibody to cross-linked fibrin for targeted delivery of anti-restenotic drugs. Journal of Controlled Release, 2004, 100, 357-377.	9.9	16
40	Role of TPBG (Trophoblast Glycoprotein) Antigen in Human Pericyte Migratory and Angiogenic Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1113-1124.	2.4	15
41	In Vitro and In Vivo Preclinical Testing of Pericyteâ€Engineered Grafts for the Correction of Congenital Heart Defects. Journal of the American Heart Association, 2020, 9, e014214.	3.7	14
42	A REPRODUCIBLE MODEL OF CHRONIC REJECTION IN RAT RENAL ALLOGRAFTS. ANZ Journal of Surgery, 1995, 65, 114-119.	0.7	13
43	Nerve growth factor gene therapy improves bone marrow sensory innervation and nociceptor-mediated stem cell release in a mouse model of type 1 diabetes with limb ischaemia. Diabetologia, 2019, 62, 1297-1311.	6.3	13
44	Timecourse of fibrin deposition and removal after arterial injury. Thrombosis Research, 2003, 109, 65-69.	1.7	11
45	Multi-Omics Analysis of Diabetic Heart Disease in the db/db Model Reveals Potential Targets for Treatment by a Longevity-Associated Gene. Cells, 2020, 9, 1283.	4.1	11
46	A humanized HLA-DR4 mouse model for autoimmune myocarditis. Journal of Molecular and Cellular Cardiology, 2017, 107, 22-26.	1.9	10
47	The pro-fibrotic and anti-inflammatory foam cell macrophage paradox. Genomics Data, 2015, 6, 136-138.	1.3	9
48	Fabrication of New Hybrid Scaffolds for in vivo Perivascular Application to Treat Limb Ischemia. Frontiers in Cardiovascular Medicine, 2020, 7, 598890.	2.4	9
49	Activation of Bone Marrow Adaptive Immunity in Type 2 Diabetes: Rescue by Co-stimulation Modulator Abatacept. Frontiers in Immunology, 2021, 12, 609406.	4.8	9
50	Contractile and cytoskeletal proteins of smooth muscle cells in rat, rabbit and human arteries. Tissue and Cell, 2000, 32, 249-256.	2.2	6
51	Smooth muscle cells of injured rat and rabbit arteries in culture: contractile and cytoskeletal proteins. Atherosclerosis, 2001, 154, 291-299.	0.8	6
52	Reconstruction of the Swine Pulmonary Artery Using a Graft Engineered With Syngeneic Cardiac Pericytes. Frontiers in Bioengineering and Biotechnology, 2021, 9, 715717.	4.1	5
53	Plaque Size Is Decreased but M1 Macrophage Polarization and Rupture Related Metalloproteinase Expression Are Maintained after Deleting T-Bet in ApoE Null Mice. PLoS ONE, 2016, 11, e0148873.	2.5	5
54	Umbilical Cord Pericytes Provide a Viable Alternative to Mesenchymal Stem Cells for Neonatal Vascular Engineering. Frontiers in Cardiovascular Medicine, 2020, 7, 609980.	2.4	3

#	Article	IF	Citations
55	Targeted Treatments for Restenosis and Vein Graft Disease. ISRN Vascular Medicine, 2012, 2012, 1-23.	0.7	2
56	Inflammatory Response in Cardiovascular Surgery. , 2013, , .		2
57	Metalloproteinases in Acute Venous Occlusion. , 2013, , 141-151.		1
58	Hemodynamic and pharmacokinetic interaction between oral verapamil and metoprolol: Evidence of altered presystemic extraction. Journal of the American College of Cardiology, 1991, 17, A139.	2.8	0
59	W12-P-075 What makes a macrophage a foam cell? Answers from genomics. Atherosclerosis Supplements, 2005, 6, 80.	1.2	0
60	Protective effects of C5a receptor antagonism in a mouse model of atherosclerosis. Molecular Immunology, 2008, 45, 4151.	2.2	0
61	BAS/BSCR8 Does macrophage foam cell formation promote extracellular matrix formation or degradation? A genomic study. Heart, 2010, 96, e14-e14.	2.9	0
62	P411 GENOMIC DIFFERENCES BETWEEN MOUSE FOAMY AND NON-FOAMY MACROPHAGES. Atherosclerosis Supplements, 2010, 11, 103-104.	1.2	0
63	P731Classical and alternative activation and metalloproteinase expression occurs in foam cell macrophages in ApoE null mice in the absence of T- and B-lymphocytes. Cardiovascular Research, 2014, 103, S134.1-S134.	3.8	0
64	171â€...Deleting TH1-lymphocytes Influences Macrophage Activation and Metalloproteinase Expression in apoe Null Mice. Heart, 2014, 100, A97.2-A97.	2.9	0
65	P730Foam cell macrophages increase fibrosis: a new paradox. Cardiovascular Research, 2014, 103, S133.5-S133.	3.8	0
66	Strategies to Extend the Life of Saphenous Vein Grafts. , 2016, , 581-593.		0
67	Macrophage polarisation and MMP production are maintained in the absence of all lymphocytes or the TH1-lymphocyte subset. Atherosclerosis, 2016, 244, e2.	0.8	0
68	Targeting Therapies to Treat Vein Graft Disease and Restenosis. , 2016, , 715-723.		0
69	Mechanical Strain Induces Transcriptomic Reprogramming of Saphenous Vein Progenitors. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	0